FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      gild

      ·

      Gilead Extends Tender Offer for Arcellx Shares

      Gilead Sciences, Inc. has announced an extension of its tender offer to acquire all outstanding shares of Arcellx. The new expiration date for the offer has not been specified, but it continues to provide a purchase price of $115.00 per share, payable in cash without interest, subject to applicable withholding taxes.

      In addition to the cash offer, shareholders will receive one contractual contingent value right (CVR) for each share tendered. This CVR entitles the holder to a potential additional payment of $5.00 in cash, also without interest. Gilead's move aims to enhance its portfolio in the biopharmaceutical sector through this acquisition.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud